174 related articles for article (PubMed ID: 25576965)
1. NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.
Kong M; Ba M; Liu C; Zhang Y; Zhang H; Qiu H
Behav Brain Res; 2015 Apr; 282():46-53. PubMed ID: 25576965
[TBL] [Abstract][Full Text] [Related]
2. Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models.
Ba M; Kong M; Ma G
Drug Des Devel Ther; 2015; 9():199-206. PubMed ID: 25565773
[TBL] [Abstract][Full Text] [Related]
3. Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model.
Ba M; Kong M; Guan L; Yi M; Zhang H
Oncotarget; 2016 Sep; 7(37):58802-58812. PubMed ID: 27613848
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Pleiotrophin and Fyn in the striatum of rats undergoing L-DOPA-induced dyskinesia.
Gomez G; Saborido MD; Bernardi MA; Gershanik OS; Taravini IR; Ferrario JE
Neurosci Lett; 2018 Feb; 666():5-10. PubMed ID: 29241709
[TBL] [Abstract][Full Text] [Related]
5. S-nitrosylation of Src by NR2B-nNOS signal causes Src activation and NR2B tyrosine phosphorylation in levodopa-induced dyskinetic rat model.
Ba M; Ding W; Guan L; Lv Y; Kong M
Hum Exp Toxicol; 2019 Mar; 38(3):303-310. PubMed ID: 30350722
[TBL] [Abstract][Full Text] [Related]
6. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
[TBL] [Abstract][Full Text] [Related]
7. The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.
Sanz-Blasco S; Bordone MP; Damianich A; Gomez G; Bernardi MA; Isaja L; Taravini IR; Hanger DP; Avale ME; Gershanik OS; Ferrario JE
Mol Neurobiol; 2018 Jun; 55(6):5125-5136. PubMed ID: 28840468
[TBL] [Abstract][Full Text] [Related]
8. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
Errico F; Bonito-Oliva A; Bagetta V; Vitucci D; Romano R; Zianni E; Napolitano F; Marinucci S; Di Luca M; Calabresi P; Fisone G; Carta M; Picconi B; Gardoni F; Usiello A
Exp Neurol; 2011 Dec; 232(2):240-50. PubMed ID: 21946266
[TBL] [Abstract][Full Text] [Related]
9. Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease.
Quintana A; Sgambato-Faure V; Savasta M
Neurobiol Dis; 2012 Dec; 48(3):379-90. PubMed ID: 22759925
[TBL] [Abstract][Full Text] [Related]
10. Tat-Src reduced NR2B tyrosine phosphorylation and its interaction with NR2B in levodopa-induced dyskinetic rats model.
Ba M; Yu G; Yang H; Wang Y; Yu L; Kong M
Behav Brain Res; 2019 Jan; 356():41-45. PubMed ID: 30130562
[TBL] [Abstract][Full Text] [Related]
11. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
Fiorentini C; Rizzetti MC; Busi C; Bontempi S; Collo G; Spano P; Missale C
Mol Pharmacol; 2006 Mar; 69(3):805-12. PubMed ID: 16365282
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
Dunah AW; Sirianni AC; Fienberg AA; Bastia E; Schwarzschild MA; Standaert DG
Mol Pharmacol; 2004 Jan; 65(1):121-9. PubMed ID: 14722243
[TBL] [Abstract][Full Text] [Related]
13. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
14. Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats.
Wang XS; Zhang ZR; Zhang XR; Chen SY; Shao B; Xie CL
Biomed Pharmacother; 2018 Nov; 107():769-776. PubMed ID: 30142538
[TBL] [Abstract][Full Text] [Related]
15. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.
Lebel M; Chagniel L; Bureau G; Cyr M
Neurobiol Dis; 2010 Apr; 38(1):59-67. PubMed ID: 20060905
[TBL] [Abstract][Full Text] [Related]
16. CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
Yang X; Zhu Z; Ding X; Wang X; Cui G; Hua F; Xiang J
Brain Res; 2018 May; 1687():66-73. PubMed ID: 29452071
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.
Rylander D; Recchia A; Mela F; Dekundy A; Danysz W; Cenci MA
J Pharmacol Exp Ther; 2009 Jul; 330(1):227-35. PubMed ID: 19357321
[TBL] [Abstract][Full Text] [Related]
18. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
Hadj Tahar A; Grégoire L; Darré A; Bélanger N; Meltzer L; Bédard PJ
Neurobiol Dis; 2004 Mar; 15(2):171-6. PubMed ID: 15006686
[TBL] [Abstract][Full Text] [Related]
19. Roles of Ca(2+)/calmodulin-dependent protein kinase II in subcellular expression of striatal N-methyl-D-aspartate receptors in l-3, 4-dihydroxyphenylalanine-induced dyskinetic rats.
Gan J; Qi C; Liu Z
Drug Des Devel Ther; 2015; 9():2119-28. PubMed ID: 25926720
[TBL] [Abstract][Full Text] [Related]
20. Involvement of spinal phosphorylation cascade of Tyr1472-NR2B, Thr286-CaMKII, and Ser831-GluR1 in neuropathic pain.
Katano T; Nakazawa T; Nakatsuka T; Watanabe M; Yamamoto T; Ito S
Neuropharmacology; 2011 Mar; 60(4):609-16. PubMed ID: 21167847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
